Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q3 FY23 results · Oct–Dec 2022
Sun Pharma Advanced Research Company reported revenue from operations of ₹131.09 crore (up 110.9% from Q3 FY22) and net profit of ₹10.15 crore for Q3 FY23 (Oct–Dec 2022), on a standalone basis.
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 131.09 | 62.15 | +110.9% | 31.54 | +315.6% |
| Other income | 0.03 | 0.34 | −91.2% | 0.06 | −50.0% |
| Total income | 131.12 | 62.49 | +109.8% | 31.60 | +314.9% |
| Profit before tax | 10.15 | (15.84) | Turned profit | (68.40) | Turned profit |
| Net profit for the period | 10.15 | (15.84) | Turned profit | (68.40) | Turned profit |
| EPS, basic (₹) | 0.37 | (0.60) | Turned profit | (2.52) | Turned profit |
| Net margin (%) | 7.7 | -25.5 | -216.9 |
Standalone
- Filed with BSE
- 13 Feb 2023, 17:17 IST
- Board meeting
- 13 Feb 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE